Health Care • Biotechnology: Pharmaceutical Preparations
$7.00 ▼ -0.33
(-4.50%)
MKT CAP: $641.4M • VOL: 751.4K
52W L $6 52W H $36
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
OLMA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$178.7M | -$142.3M | -$105.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$162.5M | -$129.5M | -$96.7M |
| EBITDA (Normalized) | — | -$142.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$146.7M | -$104.4M | -$83.7M |
| Capital Expenditures (CapEx) | — | $159.0K | — |
| Free Cash Flow (FCF) | -$146.7M | -$104.5M | -$83.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -32.8% | -41.7% | — |
| Cash & Short-Term Equivalents | $48.3M | $139.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $478.6M | $409.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OLMA.